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Background. Insulin-like growth factor (IGF-1) has been
shown in animal models to accelerate recovery from acute renal
failure (ARF). However, a therapeutic trial of recombinant hu-
man (rh) IGF-1 in patients with ARF in the intensive care unit
(ICU) failed to demonstrate efficacy [1]. Such patients often
had multiple organ failure, recurrent renal injury, and a delay
of several days before commencing treatment.
Methods. To circumvent these confounding factors, we ran-
domized recipients of cadaveric renal allografts to immediate
(5 hours) rhIGF-1 versus placebo therapy (100 mg/kg subcu-
taneously twice a day for 6 days). Preliminary observations 3
hours posttransplantation in an additional 44 patients revealed
a creatinine clearance 20 mL/min to predict protracted ARF.
Thus, this value was used to determine study eligibility.
Results. Creatinine clearance prior to commencing treatment
was not significantly different between the two groups (8  5
mL/min for IGF-1 and 7  6 mL/min for placebo; P  0.39).
Inulin clearance on day 7, the primary outcome measure, was
21 22 mL/min and 19 19 mL/min in the IGF-1 (N 19) and
placebo (N  24) groups, respectively (P  0.67). Secondary
outcome measures, including nadir serum creatinines after 6
weeks and need for dialysis, also did not differ between the
two groups. We performed an analysis of statistical power using
the placebo arm of the trial. Defining a twofold increase above
placebo in day 7 glomerular filtration rate (GFR) as of mean-
ingful biologic significance, we determined that the modest
sample size used in the present study is adequate.
Conclusion. We, thus, conclude that (1) IGF-1 treatment is
unlikely to benefit ARF and (2) the transplanted kidney is a
good model to screen new agents for ARF that have demon-
strated promise in animal trials.
The incidence rate of acute renal failure (ARF) among
patients admitted to the intensive care unit (ICU) has been
increasing for several decades and is currently estimated to
be 15% [2, 3]. Among subpopulations within the ICU,
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including those who are aged, those with multiple comor-
bidities, those with multiple organ failure, and those with
septic shock, the incidence rate of ARF can approach 50%
[4, 5]. Despite substantial advances in techniques of re-
suscitation, support of an adequate circulation and renal
replacement therapy, mortality in the critically ill popula-
tion with ARF remains alarmingly high. Even recently,
mortality rates in excess of 80% have been reported for
ICU patients with multisystem organ failure requiring
renal replacement therapy [6].
Given the high prevalence and lethality of ARF in the
ICU, an effective therapy to accelerate recovery is ur-
gently needed. A number of agents with this property
have been described in animal models of postischemic
ARF over the past decade. These include atrial natri-
uretic peptide (ANP), insulin-like growth factor (IGF-1),
inhibitors of adhesion molecules, and anti-inflammatory
neuropeptides [7–13]. In the hope that such agents might
also benefit humans with ARF, therapeutic trials of ANP
[14, 15] and recombinant human (rh) IGF-1 [1] have
recently been conducted. Disappointingly, neither of the
aforementioned agents was efficacious. It is conceivable,
however, that such lack of efficacy is primarily a conse-
quence of limitations to a therapeutic trial imposed by
ARF in the ICU setting. These include the multifactorial,
and at times uncertain etiology of the ARF, coexistence
of failure of additional organ systems, recurrent insults
to the kidney rather than a single ischemic event, and
the concomitant use of therapeutic agents that are neph-
rotoxic or lower renal blood flow. Moreover, whereas
therapy in animal models has been initiated within hours
of the ischemia/reperfusion injury to the kidney [9, 16],
corresponding therapy in the aforementioned ICU trials
was delayed by the need for many days to elapse before
the ARF could be firmly diagnosed [1, 14].
To circumvent these limitations, we have chosen to
conduct a therapeutic trial of rhIGF-1 in the postischemic
form of ARF known as “delayed graft function” (DGF).
Like animal models of ARF, DGF is precipitated by
complete interruption of the renal blood supply. Earlier
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studies have shown that this injury shares the same pa-
thology and a similar course to animal models of postis-
chemic ARF [17, 18]. Both injuries are characterized by
a severe injury to the proximal tubule that results in
transtubular backleak of filtrate [19, 20], a loss of cell
polarity, and impaired proximal sodium reabsorption
[21, 22]. Also the profound reduction in the glomerular
filtration rate (GFR) in each form of ARF can be attrib-
uted predominantly to depression of the glomerular, trans-
capillary hydraulic pressure gradient [17, 18]. Finally, as
was the case in therapeutic studies of animal models, we
were able to commence our therapeutic intervention in
patients with DGF within a few hours of reperfusion of
the transplanted kidney. Our findings form the basis of
this report.
METHODS
Patient selection
In an effort not to dilute our target population with
recipients who were destined to exhibit prompt graft
function following transplantation, we used the following
two approaches. First, we recruited only recipients of
cadaveric donor transplants and not living donor trans-
plants. Second, we recruited the former only after the
demonstration that the GFR, as determined by a 2-hour
creatinine clearance, was 20 mL/min in the immediate
posttransplant period. The creatinine clearance was per-
formed in the recovery room within an hour of transplant
kidney reperfusion. Two 60-minute urine collections
were made via a bladder catheter and blood was drawn
at the midpoint of each urine collection. The average
of the two creatinine clearances was equated with the
“effective” GFR.
The utility of the GFR 20 mL/min as a selection
criterion was first validated by collecting preliminary
data. Forty-four transplant recipients were examined on
two occasions. The first was within an hour of kidney
transplant reperfusion, as described above, and the sec-
ond examination was between the third and ninth post-
transplant day. A constant infusion technique was used
to determine the urinary clearance of inulin, along with
that of endogenous creatinine. As will be discussed in
detail below, there was no significant difference between
creatinine and inulin clearances in the range 20 mL/
min, confirming the utility of creatinine clearance as a
filtration marker under these circumstances. We next
used the days 3 to 9 GFR to classify graft function;
values 20 mL/min were classified as the sustained (or
maintenance stage), values 21 to 40 mL/min as the recov-
ering stage of DGF, and values40 mL/min were classi-
fied as within the normal range for a single kidney and
thus representative of prompt graft function [17]. We
found that a creatinine clearance20 mL/min postoper-
atively in the recovery room predicted 13 of 13 subjects
with the maintenance stage of DGF and 1 of 10 with
the recovery stage of DGF. In contrast, a postoperative
creatinine clearance of 20 mL/min was associated with
prompt graft function in 0 of 21 subjects.
Eighty-nine patients undergoing cadaveric renal trans-
plantation at our institution provided informed consent
to a trial of rhIGF-1 versus placebo for postischemic
acute renal allograft failure (Fig. 1). Each was studied
according to a research protocol approved previously by
the Panel for Research in Human Subjects at Stanford
University. All allografts were biopsied intraoperatively
and 19 of the patients randomized had a second biopsy
on postoperative day 7. Only patients with isolated post-
ischemic ARF were included in the analysis. Patients
diagnosed with ureteric obstruction, rejection, or another
renal pathology were excluded.
Study population
Sixty-four patients were diagnosed with acute renal
allograft failure based on a baseline creatinine clearance
20 mL/min (Fig. 1). Randomization was accomplished
via random number assignment by the Stanford Phar-
macy. Thus, study investigators, patients, and all individ-
uals involved in the patient’s care were blinded with
respect to the treatment provided. Blocked randomiza-
tion was utilized to ensure equal patient numbers in
the placebo and IGF-1 arms. Thirty-two patients were
randomized to each group. However, five patients in
the IGF-1 group and one patient in the placebo group
withdrew from the study. In two cases, pain at the rhIGF-1
injection site was the reason for withdrawal. No further
data were collected on any of the patients who requested
to be withdrawn from the study. Of the remaining 58
patients, five were excluded because of posttransplanta-
tion ureteric obstruction and three because of early rejec-
tion diagnosed on the day 7 biopsy. Two patients with
renal infarction, one with diarrheal contamination of all
urine studies, and another with an infected allograft were
also excluded. Of the remaining 47 patients, 26 had been
randomized to the placebo group and 21 to treatment
with IGF-1 therapy. Two patients from each group with-
drew consent to undergo an inulin clearance on day 7,
but provided urine for analysis and agreed to data collec-
tion for all secondary outcome measures (Fig. 1).
Transplantation procedures
Management of cadaveric donors. All cadaveric do-
nors in this series died of a severe brain injury. Crys-
talloid fluids and dopamine (0.1 to 0.5 g/kg/min) were
infused in an effort to maintain systolic blood pressure
above 90 mm Hg and urine flow above 50 mL/hour.
Cadaveric organ procurement was coordinated by the
California Transplant Donor Network. A neurologist in
each participating center diagnosed brain death using
clinical criteria. With the heart still beating, the donor
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Fig. 1. Patient population graphic summary
of patients recruited, randomized, and ana-
lyzed. CrCl is creatinine clearance.
was taken to an operating room, where the renal circula-
tion was exposed. To minimize the warm ischemic time,
the kidneys were first cooled in situ by flushing the renal
circulation with cold University of Wisconsin (UW) pres-
ervation solution. The kidneys were then removed and
stored in iced UW solution at 4C until transplantation.
Management of transplantation recipients. All recipi-
ents on maintenance hemodialysis were assessed clini-
cally and dialyzed if deemed necessary prior to trans-
plantation. Peritoneal catheters in recipients on chronic
peritoneal dialysis were drained and capped before sur-
gery. General anesthesia was induced with narcotic
agents and maintained with isoflurane. An indwelling
bladder catheter and a central venous line were inserted
after induction of anesthesia. The extraperitoneal space
was entered through a lower quadrant abdominal inci-
sion. The external iliac artery and vein were identified,
skeletonized for a distance of 8 cm, and clamped proxi-
mally and distally. The kidney graft was removed from
the iced storage solution and the renal artery and vein
anastomosed end-to-side to the corresponding recipient
iliac vessels. All clamps were then released. Mannitol
(0.5 g/kg) was infused just before release of the vascular
clamps. Each recipient’s bladder was filled with an irri-
gating solution containing neomycin, bacitracin, and
heparin. The donor ureter was then spatulated, the recip-
ient bladder mucosa incised, and an ureteroneocystos-
tomy created. The detrusor muscle was reapproximated
over the ureteroneocystostomy to create an antireflux
tunnel. Crystalloid solutions were infused throughout the
operative procedure to maintain central venous pressure
10 mm Hg.
Postoperative immunosuppression. The attending physi-
cian determined the immunosuppressive regimen. Induc-
tion with methylprednisolone (1 g) and azathioprine (10
mg/kg) was provided intraoperatively to most patients
(42/47). Eight patients received OKT3 induction intrave-
nously at a dose of 5 mg daily for 7 days. The maintenance
immunosuppressive regimen for the first 10 days was
composed of cyclosporin or tacrolimus in combination
with prednisone and mycophenolate mofetil. Three pa-
tients received maintenance azathioprine in place of my-
cophenolate mofetil. The calcineurin inhibitors were
used in doses to achieve whole blood trough levels of
300 to 400 ng/mL for cyclosporin and 10 to 15 ng/mL
for tacrolimus. Prednisone dosage was tapered from an
initial level of 1.5 to 1.0 mg/kg/day. Azathioprine dosage
was similarly tapered from 5 to 2 mg/kg/day.
Protocol
Donor data collected prior to randomization included
age and serum creatinine level at the time of hospital
admission. ARF in the donor prior to kidney donation
was defined as a 50% increase in serum creatinine
compared to the admission value. The “rewarming time”
(from the end of cold storage until completion of the
anastomoses) was recorded, as was the cold ischemic
time. The degree of human leukocyte antigen (HLA)
mismatch and percent of panel-reactive antibodies were
noted.
Each subject was studied on three occasions: (1) on
the day of surgery within 1 hour of vascular anastomosis
and reperfusion of the allograft (day 0), (2) on the third
postoperative day (day 3), and (3) on postoperative day
7 (day 7). In addition to the creatinine clearance, baseline
(prerandomization) measurements on the day of the
transplant included fractional excretion of sodium
(FENA), urine-to-plasma osmolality ratio, urine flow rate,
and IGF-1 serum level. The IGF-1 serum level was as-
sayed again on day 3. On day 7, clearances of creatinine
and inulin during four consecutive 30-minute urine col-
lections with corresponding serum levels were averaged.
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Table 1. Baseline characteristics
Placebo IGF-1 P value
Donor age years 4515 4017 0.28
Donor admission serum
creatinine mg/dL 0.950.5 0.910.3 0.51
Donor ARF number 10 10 0.53
HLA mismatch 42 42 0.57
PRA % 1830 1117 0.96
Cold ischemic time minutes 1042395 998484 0.73
Rewarming time minutes 3512 309 0.36
Abbreviations are: ARF, acute renal failure; HLA, human leukocyte antigen;
PRA, panel reactive antibodies. Mean value standard deviation.
GFR, as determined by the clearance of inulin, was used
as the primary outcome measure. With the exception of
another IGF-1 serum level, all baseline measurements
were repeated on postoperative day 7.
The recipients’ hospital records were reviewed to de-
termine the subsequent course of DGF beyond day 7.
Data collected included the number of dialysis sessions
and days of dialysis dependency posttransplantation, and
the nadir serum creatinine level during the first 6 weeks
posttransplantation.
IGF-1 therapy
Drug and placebo were provided by the manufacturer,
Chiron Corporation (Emoryville, CA, USA). Treatment
was commenced within 5 hours of allograft reperfusion
in all cases. rhIGF-1 was given by subcutaneous injection
in a dose of 100 g/kg of ideal body weight twice a day
for 6 days. This dose has been shown to lead to modest
and reversible side effects only after daily treatment for
2 weeks [23]. Based on the rate of tubular regeneration
and recovery from ARF in rat models [9, 10, 24, 25], we
elected to give only a 6-day course of IGF-1, a period
of therapy that has been well tolerated at a dosage of
100 g/kg twice a day in human studies [23, 26]. The
following determinations were made to monitor for side
effects: vital signs every 6 hours and a full blood count
with a general survey panel of 12 blood elements every
24 hours. Serum glucose levels were recorded 1 hour prior
to and 2 hours following each dose of IGF-1. A daily
checklist was completed to record the presence of revers-
ible side effects that have been reported by subjects re-
ceiving IGF-1, including jaw pain and tenderness, facial
edema, headache, flushing, and arthralgia/myalgia [26].
The presence of gingival hyperplasia or Bell’s palsy and
pericarditis with effusion was examined for daily [26].
Laboratory determinations
Concentrations of inulin in urine and plasma were
determined by the autoanalyzer method of Fjeldbo and
Stamey [27] using resorcinol as a colorimetric reagent.
The concentration of creatinine in urine and plasma was
determined by an automated, rate-dependent picrate
method using a creatinine analyzer (Creatinine Analyzer
2, Beckman Instruments, Fullerton, CA, USA). This
method minimizes the influence of slow-reacting noncre-
atinine chromogens and thus provides an estimate of the
true creatinine concentration. Osmolality of urine and
plasma was measured using a vapor pressure osmometer
(Model 5500, Wescor, Inc., Logan, UT, USA), while an
ion-selective electrode was used to determine corre-
sponding concentrations of sodium (Electrolyte Ana-
lyzer II, Nova Biomedical, Waltham, MA, USA). Plasma
IGF-1 levels were determined by an immunoradiometric
assay (DSL-5600 ActiveTM IGF-1 Coated Tube IRMA
Kit, Diagnostic Systems Laboratories, Inc., Webster, TX,
USA), which utilizes a modified version of the standard
acid-ethanol extraction procedure [28, 29].
Statistical analysis
For continuous variables, either a Student t test or
the Wilcoxon rank-sum test was utilized to assess the
significance of differences observed between the placebo
group and the recipients of rhIGF-1 therapy. Proportions
were compared by the chi-squared test. To determine
whether a short, timed creatinine clearance was a reason-
able substitute for inulin prior to randomization, the level
of agreement between the two markers was assessed by
the method of Bland and Altman [30]. The creatinine
clearance was compared directly to the clearance of inu-
lin for the same, single urine collection period and in-
cluded all patients participating in the present study, as
well as those who provided preliminary data. A discrimi-
nant analysis was utilized to determine if a creatinine
clearance 20 mL/min in fact predicted persistent DGF
7 days posttransplantation. The analysis included the
patients in the placebo group, those who were not ran-
domized as their baseline creatinine clearance exceeded
20 mL/min, as well as the aforementioned patients who
provided preliminary data and had a GFR measured by
inulin clearance on day 7 posttransplantation (N  44).
Sustained ARF on day 7 has been previously defined as
an inulin clearance 20 mL/min [18]. Finally, a power
analysis to determine the necessary sample sizes for in-
crements of the GFR measured by inulin clearance was
calculated for a two-sample t test with an alpha of 0.05
and 80% power. The standard deviation (SD) for the
inulin clearance of the placebo group was assumed in
performing the power analysis. SAS (version 8.2), NCSS
and PASS software were used for all statistical calcula-
tions. All results are expressed as the mean  the SD.
RESULTS
IGF-1 trial
The 47 study subjects ranged in age from 30 to 71
years, and 35 were men. Neither the donor age nor serum
creatinine levels differed between the IGF-1 and placebo
groups (Table 1). Ten donors in each group were diag-
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Table 2. Baseline renal function measurements
Placebo IGF-1 P value
Creatinine clearance mL/min 7.16.0 8.65.3 0.39
Urine flow rate mL/min 2.02.1 2.51.7 0.16
FENA % 2624 2314 0.65
U/P osmolality mOsm/kg 0.990.09 1.000.06 0.73
Abbreviations are: FENA, fractional excretion of sodium; U/P, urine-to-plasma.
Mean value standard deviation.
Fig. 2. Serum insulin-like growth factor (IGF-1) levels. Serum IGF-1
levels at baseline prior to randomization and on day 3 posttransplanta-
tion in the placebo and IGF-1 treatment groups. *P  0.0001 in IGF-1
group on day 3 compared to day 0.
nosed with ARF prior to transplantation. In addition,
the two groups were comparable with respect to the
degree of HLA mismatch, the peak percent of panel
reactive antibodies as well as the rewarming and cold
ischemic times (Table 1).
The baseline (prerandomization) evaluation of allo-
graft function, which included the creatinine clearance,
urine flow rate, FENA, and urine-to-plasma osmolality,
did not differ significantly between the placebo and treat-
ment groups (Table 2). Of note, both groups exhibited
a massive FENA in excess of 20% and isosthenuria (mean
urine-to-plasma osmolality 1.0 mOsm/kg). Evaluation
of intraoperative transplant biopsies by light and elec-
tron microscopy revealed the uniform presence in all
subjects of proximal tubular injury. This was character-
ized by focal collapse and occasional exfoliation of proxi-
mal epithelial cells by light microscopy. Absence or gross
reduction of brush border and of basolateral infoldings
were seen by electron microscopy, as reported by us
previously [17, 18]. The remaining portions of the neph-
ron were devoid of pathologic change, other than patchy
effacement of foot processes of the glomerular podocytes
[17, 18].
The serum IGF-1 level on the third day of treatment
remained unchanged from baseline in the placebo group,
270  136 ng/mL versus 225  115 ng/mL (Fig. 2). In
contrast, the serum IGF-1 increased significantly from
260 136 ng/mL to 720 324 ng/mL on day 3 of rhIGF-1
treatment (P 0.0001) (Fig. 2). However, IGF-1 therapy
failed to influence inulin clearance, the primary outcome
Fig. 3. Inulin clearance on day 7 posttransplantation. A scattergram
of individual inulin clearances on day 7. No significant difference be-
tween the group means was detected (19  19 mL/min in the placebo
group versus 21  22 mL/min in the IGF-1 group; P  0.67).
measure, on posttransplantation day 7. This value in
the treatment group (21  22 mL/min) did not differ
significantly from the corresponding value in the placebo
group (19  19 mL/min; P  0.67) (Fig. 2). Although
FENA declined significantly from baseline levels by day
7 posttransplantation in both groups, it remained mark-
edly elevated, and no significant differences between
the groups were detected (Table 3). Also isosthenuria
persisted in both groups on day 7 (Table 3). As the day
7 biopsy was optional, only 19 patients agreed, three of
which demonstrated Banff Grade IA rejection (16%).
The nadir serum creatinine in the IGF-1 group during
the first 6 weeks posttransplantation tended to be lower
than that in the placebo group (1.6  0.6 mg/dL com-
pared to 2.0  1.1 mg/dL), but this difference failed
to meet statistical significance (P  0.26). A similar,
nonsignificant trend favoring IGF-1 therapy was de-
tected in the subgroup of patients who required dialysis
(N  16) with a nadir serum creatinine of 2.0  0.8
mg/dL and 2.7 1.3 mg/dL in the treatment and placebo
groups, respectively. In addition, the difference in the
proportion of patients in each group requiring posttrans-
plantation dialysis was not significantly different with 6
of 21 (29%) in the IGF-1 treatment group and 10 of 26
(38%) in the placebo group (P 0.48). In those requiring
dialysis, the findings that most closely approached statis-
tical significance in the IGF-1 treatment group were that
they required fewer dialysis treatments (4  2 versus
8  5; P  0.05) and remained dependent on dialysis
posttransplantation for fewer days (11  4 versus 19 
10; P  0.06) compared to the placebo group.
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Table 3. Post-transplantation day 7 outcome measures
Placebo IGF-1 P value
Urine flow rate mL/min 2.11.6 2.72.6 0.37
FENA % 5.84.8 9.716.7 0.69
U/P osmolality mOsm/kg 1.050.16 1.060.21 0.76
Abbreviations are: FENA, fractional excretion of sodium; U/P, urine-to-plasma.
Mean value standard deviation.
As previously mentioned, two patients withdrew from
the study because of pain at the IGF-1 injection site.
However, hypoglycemia was not detected prior to or
following any dose of IGF-1 and none of the adverse
events among those listed in the Methods section were
observed during the course of the trial.
Human model of isolated, postischemic ARF
Creatinine clearance as a surrogate marker for the
GFR. Although a single animal study of postischemic
ARF demonstrated benefit from IGF-1 administered 24
hours following kidney reperfusion [16], in most animal
studies the IGF-1 was administered within 5 hours of
the ischemic injury [9, 16, 25, 31]. This has led to the
suggestion that the lack of benefit reported in human
ARF in a recent trial may reflect the delay of up to 6
days after the onset of renal injury before initiating ther-
apy with IGF-1 [1].
In an effort to initiate therapy with IGF-1 within hours
of allograft reperfusion, as has been the case in animal
studies of ARF [9, 16, 25, 31], we substituted creatinine
clearance for the more time-consuming inulin clearance
at baseline. Given that the creatinine transporter is lo-
cated on the proximal tubules, we reasoned that there
should be little active tubular secretion of creatinine in
the presence of postischemic ARF, and that creatinine
clearance should approximate that of a filtration marker.
The relationship between creatinine and inulin clearance
in our transplant recipients is illustrated in Figure 4.
At levels of clearance 20 mL/min, creatinine clearly
exceeds clearance of the filtration marker in most cases,
presumably reflecting recovery of tubular secretion as
the allograft recovers from ARF. At levels below 20
mL/min, the two clearances are similar, suggesting an
absence of creatinine secretion (Fig. 4). This latter rela-
tionship was analyzed by the method of Bland and Alt-
man [30]. As shown in Figure 5, the bias is only 	0.3
mL/min with a confidence interval of agreement of 
11
to 	11 mL/min. Thus, creatinine clearance appears to
behave as, and is a reasonable filtration marker in the
presence of the maintenance stage of ARF.
Predictors of the maintenance stage of DGF. We at-
tempted to discriminate between the maintenance stage
of ARF (inulin clearance 20 mL/min), the recovery
stage (inulin clearance 21 to 40 mL/min), and complete
recovery or prompt graft function (inulin clearance 40
Fig. 4. Creatinine versus inulin clearance. The creatinine clearance is
plotted as a function of the inulin clearance. Notice that when the
glomerular filtration rate (GFR) is  20 mL/min, the two measures
cluster around the line of identity (solid line). However, as the proximal
tubule recovers and GFR improves, creatinine clearance typically over-
estimates the corresponding inulin clearance due to the return of creati-
nine secretion.
Fig. 5. Bland and Altman measure of agreement between clearances.
Displayed is the measure of agreement between two methods utilized
to determine the glomerular filtration rate (GFR), creatinine clearance
versus the gold standard, inulin clearance. At or below 20 mL/min
of GFR, as determined by inulin clearance, the creatinine clearance
approximates the gold standard well with a bias of only 	0.3 mL/min
(solid line) and an interval of agreement of
11 to	11 mL/min (dashed
line).
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Table 4. Percent misclassification by baseline, prerandomization
creatinine clearance
Baseline creatinine clearance N Misclassification
20 mL/min (30) 33%
15 mL/min (27) 27%
10 mL/min (24) 20%
10 mL/min (19) 10%
The table demonstrates the percent of patients in the placebo group who have
entered the recovery stage or have normal kidney function by day 7 posttrans-
plantation for a given level of baseline creatinine clearance.
mL/min) on posttransplantation day 7. Three indepen-
dent baseline (prerandomization) variables, creatinine
clearance, FENA, and urine-to-plasma osmolality, were
entered into a stepwise discriminant analysis. Of the
three variables, the model retained only creatinine clear-
ance (P  0.0001). Baseline creatinine clearance alone
as a discriminant function resulted in a 52% reduction
in misclassification error over what would be expected
if observations were randomly classified into the three
aforementioned levels of acute renal injury. Of note,
creatinine clearance preformed best in the maintenance
category of ARF. However, the extent to which creati-
nine clearance 20 mL/min at baseline resulted in a
misclassification of patients who had sustained (mainte-
nance stage) ARF on day 7 (inulin clearance 20 mL/
min) is summarized in Table 4. As shown, 33% had
already entered the recovery stage, judged by an inulin
clearance 20 mL/min at this time. The degree of mis-
classification is shown to decline at lower baseline values
of creatinine clearance falling to only 27% and 10% at
values of 15 mL/min and 10 mL/min, respectively
(Table 4).
Power analysis. Based on the distribution of inulin
clearance in the placebo group on day 7, the necessary
sample sizes for increments of effect size were calculated.
Although an effect size of 25% in many clinical situations
is deemed excellent, this would translate into an incre-
ment of only 5 mL/min of GFR, an amount inadequate
to allow for the discontinuation of renal replacement
therapy or have a meaningful impact on the outcome of
ARF in the ICU. As shown in Table 5, whereas such a
small effect size of 5 mL/min would require 227 patients
per arm, increments of 15 or 20 mL/min require corre-
sponding samples of only 26 and 15, respectively. We
thus submit that even the small sample studied should
have been adequate to demonstrate a biologically mean-
ingful effect of rhIGF-1 on the form of postischemic
ARF encountered in the present study.
DISCUSSION
Our trial of IGF-1 used an ischemic/reperfusion injury
to the renal allograft as an analog of postischemic ARF
in humans. In keeping with an earlier study by Hirsch-
Table 5. Power analysis
Effect size Placebo Drug
5 mL/min 227 227
10 mL/min 57 57
15 mL/min 26 26
20 mL/min 15 15
The necessary sample sizes for increments of the glomerular filtration rate
(GFR) (effect size) measured by inulin clearance calculated for a two-sample t
test with an alpha of 0.05 and 80% power, assuming the standard deviation for
the inulin clearance of the placebo group.
berg et al [1] of native kidney ARF in an ICU setting,
IGF-1 failed to benefit our subjects with DGF. The clear-
ance of inulin on day 7, our primary outcome measure,
was similarly depressed in our IGF-1 and placebo-treated
subjects, 21 22 mL/min versus 19 19 mL/min, respec-
tively (Fig. 3). These values are only 25% of corre-
sponding values in optimally functioning renal allografts
[18, 32]. They were also associated with marked impair-
ment of sodium reabsorption and isosthenuria, indicating
persistent tubular dysfunction (Table 2). This disappoint-
ing result eventuated despite our success in initiating
the therapy within 5 hours of allograft reperfusion and
avoiding virtually all of the variables that confounded
the aforementioned earlier ICU study of IGF-1 therapy
for ARF [1].
On the other hand, our trial did reveal in subjects
treated with IGF-1, a trend beyond day 7 toward an
abbreviated and more efficient stage of recovery of DGF,
one that approached statistical significance. This trend
was manifest among those requiring renal replacement
therapy as a shorter period of dialysis dependency (11 4
days versus 19  10 days, P  0.06), a need for fewer
dialysis sessions (4 2 versus 8 5, P 0.05) and a lower
nadir serum creatinine level during the first 6 weeks
posttransplant (2.0  0.8 mg/dL and 2.7  1.3 mg/dL,
P  0.27) in the IGF-1 than the placebo-treated group,
respectively.
The apparent failure of IGF-1 therapy to improve the
maintenance stage (as judged by our day 7 findings),
while possibly improving the late recovery stage of this
form of postischemic ARF, represents an interesting par-
adox. It is at odds with the effect of IGF-1 to modify
the course of the post-clamp model of postischemic ARF
in the rat [9, 10, 24, 25]. In a series of studies of this
latter injury during the 1990s, postischemic injury was
induced by transiently clamping both renal arteries for
between 35 and 70 minutes, and then commencing 2 to
7 days of IGF-1 treatment in divided doses, beginning
0.5 to 24 hours after clamp release and reperfusion [9, 10,
24, 25]. Under these conditions, IGF-1 therapy uniformly
accelerated recovery from the ARF, such that the main-
tenance rather than the recovery stage was markedly
abbreviated. GFR determined on day 2 or 3 postinjury
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in the IGF-1–treated rats was elevated above corre-
sponding placebo-treated levels by a factor of two- to
fivefold [9, 25, 31]. As a result, whereas azotemia per-
sisted in placebo-treated animals, it had resolved almost
completely within 7 days in those animals that received
IGF-1.
The absence of an effect of IGF-1 to shorten the main-
tenance stage of DGF in the present study could reflect
differences in this form of ARF from the aforementioned
animal model. Obvious differences include the prolonged
“cold” ischemia that precipitates the injury and the use
of potentially renal vasoconstrictor doses of calcineurin
inhibitors, during (and after) the course of IGF-1 ther-
apy. However, IGF-1 has been shown to ameliorate cyclo-
sporin nephrotoxicity in an animal model of DGF [33].
In addition, it is conceivable that patients who did not
consent to a second biopsy also had unrecognized rejec-
tion. Alternatively, it could reflect inadequate IGF-1 dos-
age in our transplant recipients, an unlikely explanation,
since the regimen employed has been shown to increase
GFR and renal plasma flow in humans with chronic renal
failure [23]. Rather, we suspect that the apparent trend
to shortening of the recovery stage by IGF-1 in our
subjects could be spurious. We propose additional study
is necessary to determine whether the phenomenon is
real and meaningful.
The lack of efficacy of IGF-1 therapy in humans with
ARF that we and others [1] have observed is a reprise
of an earlier experience with trials of therapy with ANP.
An optimism in the nephrology community that IGF-1
therapy of ARF in humans would succeed where ANP
had failed was based on the observation that, in addition
to its vasodilator actions [34, 35], IGF-1 was expressed
in regenerating proximal tubule epithelial cells during
postischemic injury in the rat [36, 37]. Its efficacy in rat
models was postulated to reflect an action to serve as a
mitogen and regenerate a proximal tubule lined by cells
with normal polarity and reabsorptive capacity. The sub-
sequent lack of efficacy of IGF-1 demonstrated in human
ARF casts doubt upon this postulate. It also raises doubts
about the efficacy in human ARF of hepatic and other
growth factors that have proved effective in rat models
of ARF [16]. To this must be added a growing list of other
agents that have been reported to accelerate recovery in
rodent models of postischemic ARF [38]. Given that
evidence to support an identical mechanism in human
ARF is scanty, it is necessary to consider the possibility
that rodent models of postischemic ARF are fundamen-
tally different from the human injury that they have been
designed to simulate. This raises the possibility of an
endless series of therapeutic trials of agents that are
effective in the rat, but could prove futile in humans
with ARF.
Given the aforementioned possibility, we submit that
DGF is an ideal and economic model with which to
screen therapeutic agents for ARF before designing large
and expensive controlled trials of subjects with native
kidney ARF in the ICU setting. As stated previously,
DGF can be diagnosed early, allowing therapeutic inter-
vention within hours of allograft reperfusion, whereas
native kidney ARF takes 3 to 6 days to identify and
diagnose in an ICU setting, thereby delaying the initia-
tion of therapy [39]. The early intervention in DGF is
made possible by performing a creatinine clearance within
3 hours of transplant reperfusion so as to predict an epi-
sode of ARF that will be sufficiently protracted to result
in the sustained or maintenance stage of ARF after 7
days. As shown in Table 4, using a baseline creatinine
clearance of less than 10 mL/min could limit the misclas-
sification rate of subjects who already have entered the
recovery stage of ARF by day 7 to only 10%, as opposed
to the 33% misclassified by using a baseline clearance
20 mL/min as in the present study. Excluding as many
subjects as possible destined to manifest recovery by
day 7 should enhance statistical power and facilitate the
identification of efficacy of a given agent. Additional
measures to enhance statistical power would be the rou-
tine performance of an allograft biopsy and ultrasonic
imaging on day 7, so as to exclude injuries that are unre-
lated to postischemic ARF, notably acute rejection and
ureteric obstruction.
In addition to early initiation, the DGF model has
several other advantages that make it useful as a way to
screen for therapeutic efficacy of new potential agents.
One such advantage is a more predictable course, a con-
sequence of a single ischemic insult rather than the multi-
ple, repeated episodes of renal ischemia that often occur
in subjects with native kidney ARF in the ICU setting
[39]. Another is that transplant recipients do not have
multiple organ failure, and are in fact, in good general
condition, permitting the acute renal injury of DGF to
be studied in virtual isolation. A final advantage that, in
turn, is clearly related to all the other advantages already
discussed is that there is sufficient statistical power for
trials of therapy in DGF with sample sizes that are far
more modest than those required for the study of native
kidney ARF in the ICU.
A power analysis of our placebo group indicates that
to detect a biologically meaningful effect of a given agent
would require a total sample size of only 30 to 52 subjects
(Table 5). We define a biologically meaningful effect here
as one, which recapitulates that observed in clamp mod-
els of ARF in the rat in which ANP or IGF-1 virtually
normalizes GFR after a week of therapy [7, 9, 10, 13,
24, 25].
CONCLUSION
We predict that the list of agents that are efficacious
in rodent models of postischemic ARF will continue to
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grow. We submit that few, if any, of these agents are
likely to prove efficacious in postischemic ARF in hu-
mans. Because controlled trials of native kidney ARF
in the ICU are a costly and complex undertaking, we
propose that the syndrome of DGF first be used to screen
those agents that are likely to prove useful in humans.
The ability to initiate therapy early, the paucity of con-
founding factors, and the small sample size required for
statistical power make DGF an excellent model for the
first line of investigation of new therapy in postischemic
ARF in humans.
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